Concepts (148)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Tissue and Organ Procurement | 8 | 2022 | 247 | 2.840 |
Why?
|
| Liver Transplantation | 24 | 2025 | 1128 | 2.790 |
Why?
|
| Tissue Donors | 14 | 2022 | 523 | 2.270 |
Why?
|
| Organ Transplantation | 5 | 2025 | 186 | 1.910 |
Why?
|
| Donor Selection | 3 | 2020 | 58 | 1.380 |
Why?
|
| Kidney Transplantation | 7 | 2022 | 691 | 1.350 |
Why?
|
| Graft Rejection | 6 | 2025 | 630 | 1.180 |
Why?
|
| Thrombosis | 3 | 2022 | 547 | 1.150 |
Why?
|
| Transplant Recipients | 6 | 2025 | 227 | 0.970 |
Why?
|
| Kidney Failure, Chronic | 4 | 2021 | 915 | 0.840 |
Why?
|
| Death | 2 | 2021 | 80 | 0.810 |
Why?
|
| Venous Thrombosis | 2 | 2022 | 173 | 0.800 |
Why?
|
| Immunosuppressive Agents | 2 | 2025 | 703 | 0.680 |
Why?
|
| Waiting Lists | 6 | 2024 | 244 | 0.670 |
Why?
|
| Health Care Rationing | 1 | 2020 | 63 | 0.650 |
Why?
|
| Graft Survival | 10 | 2022 | 557 | 0.630 |
Why?
|
| Vena Cava, Inferior | 1 | 2019 | 103 | 0.590 |
Why?
|
| Immunocompromised Host | 1 | 2020 | 306 | 0.590 |
Why?
|
| Perioperative Care | 1 | 2020 | 211 | 0.580 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2019 | 138 | 0.570 |
Why?
|
| Liver Diseases | 1 | 2022 | 392 | 0.570 |
Why?
|
| Betacoronavirus | 1 | 2020 | 306 | 0.520 |
Why?
|
| End Stage Liver Disease | 5 | 2024 | 203 | 0.510 |
Why?
|
| Patient Selection | 1 | 2020 | 735 | 0.510 |
Why?
|
| Portal Vein | 3 | 2022 | 95 | 0.510 |
Why?
|
| Pandemics | 2 | 2020 | 1190 | 0.490 |
Why?
|
| Health Services Accessibility | 1 | 2020 | 649 | 0.450 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 385 | 0.450 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 396 | 0.450 |
Why?
|
| Registries | 1 | 2019 | 1578 | 0.370 |
Why?
|
| Length of Stay | 5 | 2021 | 1391 | 0.350 |
Why?
|
| Child | 23 | 2025 | 25890 | 0.350 |
Why?
|
| Humans | 42 | 2025 | 134156 | 0.330 |
Why?
|
| Retrospective Studies | 24 | 2025 | 17540 | 0.320 |
Why?
|
| Adolescent | 17 | 2025 | 20624 | 0.310 |
Why?
|
| Iliac Vein | 2 | 2019 | 30 | 0.300 |
Why?
|
| Child, Preschool | 16 | 2025 | 14884 | 0.300 |
Why?
|
| Allografts | 5 | 2021 | 198 | 0.300 |
Why?
|
| Vascular Grafting | 2 | 2019 | 48 | 0.300 |
Why?
|
| Biliary Atresia | 2 | 2023 | 206 | 0.280 |
Why?
|
| Risk Factors | 16 | 2025 | 11182 | 0.250 |
Why?
|
| Treatment Outcome | 12 | 2024 | 13074 | 0.250 |
Why?
|
| Infant | 14 | 2025 | 13240 | 0.250 |
Why?
|
| Decision Support Techniques | 2 | 2019 | 319 | 0.240 |
Why?
|
| Hypernatremia | 1 | 2024 | 33 | 0.220 |
Why?
|
| Male | 23 | 2025 | 66127 | 0.210 |
Why?
|
| Sirolimus | 1 | 2025 | 253 | 0.200 |
Why?
|
| Adenovirus Infections, Human | 1 | 2023 | 57 | 0.200 |
Why?
|
| Hepatic Artery | 1 | 2022 | 51 | 0.190 |
Why?
|
| Catheters | 1 | 2022 | 89 | 0.180 |
Why?
|
| Postoperative Period | 2 | 2020 | 343 | 0.180 |
Why?
|
| Liver Failure, Acute | 1 | 2023 | 96 | 0.180 |
Why?
|
| Hepatoblastoma | 1 | 2023 | 184 | 0.180 |
Why?
|
| Thrombectomy | 1 | 2021 | 107 | 0.170 |
Why?
|
| Age Factors | 6 | 2021 | 2998 | 0.170 |
Why?
|
| Severity of Illness Index | 2 | 2020 | 3114 | 0.170 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2021 | 121 | 0.170 |
Why?
|
| Hospitalization | 2 | 2020 | 1906 | 0.170 |
Why?
|
| Respiration, Artificial | 1 | 2023 | 501 | 0.170 |
Why?
|
| Kaplan-Meier Estimate | 5 | 2024 | 1146 | 0.160 |
Why?
|
| Twins, Conjoined | 1 | 2020 | 30 | 0.160 |
Why?
|
| Public Opinion | 1 | 2020 | 62 | 0.160 |
Why?
|
| Attitude | 1 | 2020 | 122 | 0.160 |
Why?
|
| Gastroenteritis | 1 | 2023 | 365 | 0.160 |
Why?
|
| Learning Curve | 1 | 2020 | 57 | 0.160 |
Why?
|
| Printing, Three-Dimensional | 1 | 2020 | 70 | 0.160 |
Why?
|
| Models, Anatomic | 1 | 2020 | 104 | 0.160 |
Why?
|
| Renal Veins | 1 | 2019 | 34 | 0.160 |
Why?
|
| Directed Tissue Donation | 1 | 2019 | 3 | 0.160 |
Why?
|
| Female | 21 | 2025 | 71928 | 0.160 |
Why?
|
| Tetrazoles | 1 | 2019 | 64 | 0.150 |
Why?
|
| Clinical Protocols | 1 | 2020 | 245 | 0.150 |
Why?
|
| Anastomosis, Surgical | 1 | 2019 | 166 | 0.150 |
Why?
|
| Infant, Newborn | 6 | 2024 | 8623 | 0.150 |
Why?
|
| Cold Ischemia | 1 | 2018 | 22 | 0.150 |
Why?
|
| Blood Loss, Surgical | 1 | 2019 | 158 | 0.140 |
Why?
|
| Cardiomyopathies | 1 | 2023 | 519 | 0.140 |
Why?
|
| Tissue and Organ Harvesting | 1 | 2018 | 40 | 0.140 |
Why?
|
| Erythrocyte Transfusion | 1 | 2019 | 135 | 0.140 |
Why?
|
| Imidazoles | 1 | 2019 | 220 | 0.140 |
Why?
|
| Anticoagulants | 1 | 2022 | 615 | 0.130 |
Why?
|
| Liver Failure | 1 | 2017 | 91 | 0.130 |
Why?
|
| Blood Group Incompatibility | 1 | 2016 | 27 | 0.120 |
Why?
|
| Kidney | 2 | 2022 | 1421 | 0.120 |
Why?
|
| Liver Cirrhosis, Biliary | 1 | 2016 | 88 | 0.120 |
Why?
|
| ABO Blood-Group System | 1 | 2016 | 69 | 0.120 |
Why?
|
| Quality Improvement | 1 | 2021 | 700 | 0.120 |
Why?
|
| Aorta | 1 | 2019 | 564 | 0.120 |
Why?
|
| Heart Transplantation | 1 | 2022 | 904 | 0.110 |
Why?
|
| Models, Statistical | 1 | 2017 | 505 | 0.110 |
Why?
|
| Reoperation | 1 | 2018 | 856 | 0.110 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2023 | 1007 | 0.110 |
Why?
|
| Adult | 10 | 2022 | 31945 | 0.110 |
Why?
|
| Critical Care | 2 | 2017 | 693 | 0.110 |
Why?
|
| Liver Neoplasms | 1 | 2023 | 1417 | 0.100 |
Why?
|
| Follow-Up Studies | 5 | 2022 | 5477 | 0.100 |
Why?
|
| United States | 5 | 2020 | 11763 | 0.100 |
Why?
|
| Body Weight | 2 | 2019 | 1041 | 0.100 |
Why?
|
| Transplantation, Homologous | 3 | 2022 | 690 | 0.100 |
Why?
|
| Proportional Hazards Models | 4 | 2019 | 1488 | 0.100 |
Why?
|
| Liver | 4 | 2020 | 1879 | 0.090 |
Why?
|
| Logistic Models | 3 | 2024 | 1909 | 0.090 |
Why?
|
| Cross-Sectional Studies | 1 | 2020 | 3754 | 0.090 |
Why?
|
| Survival Rate | 3 | 2022 | 2218 | 0.080 |
Why?
|
| Pediatrics | 1 | 2019 | 1215 | 0.080 |
Why?
|
| Multivariate Analysis | 2 | 2024 | 1492 | 0.070 |
Why?
|
| Prognosis | 3 | 2024 | 5086 | 0.070 |
Why?
|
| Middle Aged | 8 | 2020 | 29399 | 0.060 |
Why?
|
| Aged | 7 | 2020 | 21775 | 0.060 |
Why?
|
| Liver Cirrhosis | 2 | 2023 | 947 | 0.060 |
Why?
|
| Postoperative Complications | 1 | 2018 | 3178 | 0.060 |
Why?
|
| Intention to Treat Analysis | 1 | 2024 | 66 | 0.060 |
Why?
|
| Young Adult | 4 | 2020 | 9944 | 0.050 |
Why?
|
| Hyponatremia | 1 | 2024 | 76 | 0.050 |
Why?
|
| Sodium | 1 | 2024 | 309 | 0.050 |
Why?
|
| Acute Disease | 2 | 2016 | 1192 | 0.050 |
Why?
|
| Predictive Value of Tests | 2 | 2019 | 2301 | 0.050 |
Why?
|
| Adenoviruses, Human | 1 | 2023 | 99 | 0.050 |
Why?
|
| GTP-Binding Proteins | 1 | 2023 | 188 | 0.050 |
Why?
|
| Sex Factors | 1 | 2025 | 1387 | 0.040 |
Why?
|
| Protective Factors | 1 | 2021 | 92 | 0.040 |
Why?
|
| Bile Acids and Salts | 1 | 2023 | 259 | 0.040 |
Why?
|
| Adenoviridae | 1 | 2023 | 609 | 0.040 |
Why?
|
| Risk Assessment | 2 | 2019 | 3743 | 0.040 |
Why?
|
| Intraoperative Care | 1 | 2019 | 120 | 0.040 |
Why?
|
| Operative Time | 1 | 2019 | 189 | 0.040 |
Why?
|
| Time Factors | 2 | 2019 | 6610 | 0.040 |
Why?
|
| Health Status Disparities | 1 | 2021 | 250 | 0.040 |
Why?
|
| Lymphocytes | 1 | 1999 | 442 | 0.030 |
Why?
|
| Regression Analysis | 1 | 2019 | 827 | 0.030 |
Why?
|
| Translocation, Genetic | 1 | 1999 | 363 | 0.030 |
Why?
|
| Clinical Decision-Making | 1 | 2019 | 298 | 0.030 |
Why?
|
| Cohort Studies | 2 | 2016 | 5222 | 0.030 |
Why?
|
| Cause of Death | 1 | 2016 | 507 | 0.030 |
Why?
|
| Risk | 1 | 2016 | 837 | 0.030 |
Why?
|
| Intensive Care Units | 1 | 2017 | 538 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2018 | 1258 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2017 | 1310 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2016 | 1599 | 0.020 |
Why?
|
| Critical Illness | 1 | 2017 | 629 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2018 | 3043 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2016 | 1719 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2016 | 7217 | 0.010 |
Why?
|
| Relative Biological Effectiveness | 1 | 1999 | 8 | 0.010 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 1999 | 74 | 0.010 |
Why?
|
| Temperature | 1 | 1999 | 330 | 0.010 |
Why?
|
| DNA Damage | 1 | 1999 | 547 | 0.010 |
Why?
|
| DNA Repair | 1 | 1999 | 635 | 0.010 |
Why?
|